Renin-angiotensin-aldosterone signaling inhibitors—losartan, enalapril, and cardosten—prevent infarction-induced heart failure development in rats

Alternative Therapies in Health and Medicine

Volumn 22, Issue 2, 2016, Pages 10-17

  Kiss, Krisztina ^a   Fekete, Veronika ^b   Pálóczi, János ^c   Sárközy, Márta ^b   Murlasits, Zsolt ^d   Pipis, Judit ^c   Kheyfets, Irina A ^e   Dugina, Julia L ^e   Sergeeva, Svetlana A ^e   Epstein, Oleg I ^e   Csonka, Csaba ^b   Csont, Tamás ^b   Ferdinandy, Péter ^c   Bencsik, Péter ^b  

^a UNIVERSITY OF SZEGED   (Hungary)

^b UOS   (Hungary)

^c Pharmahungary Group ^*  (Hungary)

^d PHARMAHUNGARY GROUP   (Hungary)

^e OOO NPF Materia Medica Holding   (Russian Federation)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; LOSARTAN;

ANIMAL; DRUG EFFECTS; HEART; HEART FAILURE; HEART FUNCTION TEST; HEART INFARCTION; MALE; PATHOPHYSIOLOGY; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; WISTAR RAT;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ENALAPRIL; HEART; HEART FAILURE; HEART FUNCTION TESTS; LOSARTAN; MALE; MYOCARDIAL INFARCTION; RATS; RATS, WISTAR; RENIN-ANGIOTENSIN SYSTEM;

EID: 84962376867     PISSN: 10786791     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Opie LH, Commerford PJ, Gersh BJ, Pfeffer MA. Controversies in ventricular remodelling. Lancet. 2006; 367(9507): 356-367.
2. Frohlich ED. Renin-angiotensin system inhibition improves coronary flow reserve in hypertension. J Cardiovasc Pharmacol. 2001; 37(suppl 1): S35-S39.
3. Opie LH, Sack MN. Enhanced angiotensin II activity in heart failure: reevaluation of the counterregulatory hypothesis of receptor subtypes. Circ Res. 2001; 88(7): 654-658.
4. Guo X, Chapman D, Dhalla NS. Partial prevention of changes in SR gene expression in congestive heart failure due to myocardial infarction by enalapril or losartan. Mol Cell Biochem. 2003; 254(1-2): 163-172.
5. Dickstein K, Kjekshus J; OPTIMAAL Steering Committee of the OPTIMAAL Study Group. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial: optimal trial in myocardial infarction with angiotensin II antagonist losartan. Lancet. 2002; 360(9335): 752-760.
6. Pfeffer MA, Braunwald E, Moyé LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the survival and ventricular enlargement trial: the SAVE Investigators. N Engl J Med. 1992; 327(10): 669-677.
7. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet. 1993; 342(8875): 821-828.
8. Weber MA. Angiotensin II receptor blockers and cardiovascular outcomes: what does the future hold? J Renin Angiotensin Aldosterone Syst. 2003; 4(2): 62-73.
9. White HD, Aylward PE, Huang Z, et al; VALIANT Investigators. Mortality and morbidity remain high despite captopril and/or valsartan therapy in elderly patients with left ventricular systolic dysfunction, heart failure, or both after acute myocardial infarction: results from the Valsartan in Acute Myocardial Infarction Trial (VALIANT). Circulation. 2005; 112(22): 3391-3399.
10. Swedberg K, Held P, Kjekshus J, Rasmussen K, Rydén L, Wedel H. Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction: results of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II). N Engl J Med. 1992; 327(10): 678-684.
11. Molodavkin GM, Voronina TA, Cherniavskaia LI, Burlakova EB. Effects of psychotropic drugs of different classes injected in super small doses [in Russian]. Radiats Biol Radioecol. 2003; 43(3): 287-290.
12. Bell IR, Lewis DA II, Brooks AJ, et al. Improved clinical status in fibromyalgia patients treated with individualized homeopathic remedies versus placebo. Rheumatology (Oxford). 2004; 43(5): 577-582.
13. Frass M, Linkesch M, Banyai S, et al. Adjunctive homeopathic treatment in patients with severe sepsis: a randomized, double-blind, placebo-controlled trial in an intensive care unit: 2005. Homeopathy. 2011; 100(1-2): 95-100.
14. Movafegh A, Shoeibi G, Ansari M, Sadeghi M, Azimaraghi O, Aghajani Y. Naloxone infusion and post-hysterectomy morphine consumption: a doubleblind, placebo-controlled study. Acta Anaesthesiol Scand. 2012; 56(10): 1241-1249.
15. Ross JL, Quigley CA, Cao D, et al. Growth hormone plus childhood low-dose estrogen in Turner's syndrome. N Engl J Med. 2011; 364(13): 1230-1242.
16. Simon J, Nachtigall L, Ulrich LG, Eugster-Hausmann M, Gut R. Endometrial safety of ultra-low-dose estradiol vaginal tablets. Obstet Gynecol. 2010; 116(4): 876-883.
17. Tiurenkov IN, Nazvanova AN, Tchepurina NG, et al. Comparison of the cardioprotective effects of cardos and losartan in rats with experimental chronic cardiac insufficiency. Bull Exp Biol Med. 2007; 143(4): 434-436.
18. Institute of Laboratory Animal Resources, Commission on Life Sciences, National Research Council. Guide for the Care and Use of Laboratory Animals. Washington, DC: National Academy Press; 1996. NIH publication 85-23.
19. Epstein OI. Release-activity: a long way from phenomenon to new drugs. Bull Exp Biol Med. 2012; 154(1): 54-58.
20. Council of Europe, European Directorate for the Quality of Medicines. European Pharmacopoeia. 6th ed. Strasbourg, France: Council of Europe; 2007.
21. Csonka C, Szilvássy Z, Fülöp F, et al. Classic preconditioning decreases the harmful accumulation of nitric oxide during ischemia and reperfusion in rat hearts. Circulation. 1999; 100(22): 2260-2266.
22. Csont T, Csonka C, Kovács P, Jancsó G, Ferdinandy P. Capsaicin-sensitive sensory neurons regulate myocardial nitric oxide and cGMP signaling. Eur J Pharmacol. 2003; 476(1-2): 107-113.
23. Csont T, Szilvássy Z, Fülöp F, et al. Direct myocardial anti-ischaemic effect of GTN in both nitrate-tolerant and nontolerant rats: a cyclic GMP-independent activation of KATP. Br J Pharmacol. 1999; 128(7): 1427-1434.
24. Stauss HM, Zhu YC, Redlich T, et al. Angiotensin-converting enzyme inhibition in infarct-induced heart failure in rats: bradykinin versus angiotensin II. J Cardiovasc Risk. 1994; 1(3): 255-262.
25. Babick A, Chapman D, Zieroth S, Elimban V, Dhalla NS. Reversal of subcellular remodelling by losartan in heart failure due to myocardial infarction. J Cell Mol Med. 2012; 16(12): 2958-2967.
26. Ishikawa Y, Uechi M, Hori Y, et al. Effects of enalapril in cats with pressure overload-induced left ventricular hypertrophy. J Feline Med Surg. 2007; 9(1): 29-35.
27. Tamura T, Said S, Harris J, Lu W, Gerdes AM. Reverse remodeling of cardiac myocyte hypertrophy in hypertension and failure by targeting of the reninangiotensin system. Circulation. 2000; 102(2): 253-259.
28. Fujii M, Wada A, Ohnishi M, et al. Endogenous bradykinin suppresses myocardial fibrosis through the cardiac-generated endothelin system under chronic angiotensin-converting enzyme inhibition in heart failure. J Cardiovasc Pharmacol. 2004; 44(suppl 1): S346-S349.
29. Crespo MJ, Cruz N, Altieri PI, Escobales N. Enalapril and losartan are more effective than carvedilol in preventing dilated cardiomyopathy in the Syrian cardiomyopathic hamster. J Cardiovasc Pharmacol Ther. 2008; 13(3): 199-206.
30. Murakami M, Suzuki H, Naitoh M, et al. Blockade of the renin-angiotensin system in heart failure in conscious dogs. J Hypertens. 1995; 13(12, pt 1): 1405-1412.
31. Smits JF, van Krimpen C, Schoemaker RG, Cleutjens JP, Daemen MJ. Angiotensin II receptor blockade after myocardial infarction in rats: effects on hemodynamics, myocardial DNA synthesis, and interstitial collagen content. J Cardiovasc Pharmacol. 1992; 20(5): 772-778.
32. Sanbe A, Takeo S. Long-term treatment with angiotensin I-converting enzyme inhibitors attenuates the loss of cardiac beta-adrenoceptor responses in rats with chronic heart failure. Circulation. 1995; 92(9): 2666-2675.
33. Martínez LA, Villalobos-Molina R. Early and chronic captopril or losartan therapy reduces infarct size and avoids congestive heart failure after myocardial infarction in rats. Arch Med Res. 2003; 34(5): 357-361.
34. Mento PF, Maita ME, Wilkes BM. Renal hemodynamics in rats with myocardial infarction: selective antagonism of angiotensin receptor subtypes. Am J Physiol. 1996; 271(6, pt 2): H2306-H2312.
35. Nikolaidis LA, Doverspike A, Huerbin R, Hentosz T, Shannon RP. Angiotensinconverting enzyme inhibitors improve coronary flow reserve in dilated cardiomyopathy by a bradykinin-mediated, nitric oxide-dependent mechanism. Circulation. 2002; 105(23): 2785-2790.
36. Qiu CB, Qiu CS, Hess P, Clozel JP, Clozel M. Additional effects of endothelin receptor blockade and angiotensin converting enzyme inhibition in rats with chronic heart failure. Acta Pharmacol Sin. 2001; 22(6): 541-548.
37. Sunagawa Y, Morimoto T, Wada H, et al. A natural p300-specific histone acetyltransferase inhibitor, curcumin, in addition to angiotensin-converting enzyme inhibitor, exerts beneficial effects on left ventricular systolic function after myocardial infarction in rats. Circ J. 2011; 75(9): 2151-2159.
38. Crozier I, Ikram H, Awan N, et al. Losartan in heart failure: hemodynamic effects and tolerability: Losartan Hemodynamic Study Group. Circulation. 1995; 91(3): 691-697.
39. Gottlieb SS, Dickstein K, Fleck E, et al. Hemodynamic and neurohormonal effects of the angiotensin II antagonist losartan in patients with congestive heart failure. Circulation. 1993; 88(4, pt 1): 1602-1609.
40. Liu YH, Xu J, Yang XP, Yang F, Shesely E, Carretero OA. Effect of ACE inhibitors and angiotensin II type 1 receptor antagonists on endothelial NO synthase knockout mice with heart failure. Hypertension. 2002; 39(2, pt 2): 375-381.
41. Sato H, Yaoita H, Maehara K, Maruyama Y. Attenuation of heart failure due to coronary stenosis by ACE inhibitor and angiotensin receptor blocker. Am J Physiol Heart Circ Physiol. 2003; 285(1): H359-H368.
42. Hiona A, Lee AS, Nagendran J, et al. Pretreatment with angiotensin-converting enzyme inhibitor improves doxorubicin-induced cardiomyopathy via preservation of mitochondrial function. J Thorac Cardiovasc Surg. 2011; 142(2): 396-403.
43. Richer C, Fornes P, Domergue V, De Gasparo M, Giudicelli JF. Combined angiotensin II AT1-receptor blockade and angiotensin I-converting enzyme inhibition on survival and cardiac remodeling in chronic heart failure in rats. J Card Fail. 2001; 7(3): 269-276.
44. Sweet CS, Ludden CT, Stabilito II, Emmert SE, Heyse JF. Beneficial effects of milrinone and enalapril on long-term survival of rats with healed myocardial infarction. Eur J Pharmacol. 1988; 147(1): 29-37.
45. Pal'mina NP, Mal'tseva EL, Kurnakova NV, Burlakova EB. The effect of alphatocopherol over a wide range of concentrations (10(-2)-10(-17) M) on protein kinase C activity: connection with proliferation and tumor growth [in Russian]. Biokhimiia. 1994; 59(2): 193-200.
46. Roy R, Tiller WA, Bell I, Hoover MR. The structure of liquid water; novel insights from materials research; potential relevance to homeopathy. Indian J Res Homeopath. 2009; 3(2): 1-24.